Medigen Vaccine Biologics Corporation (TPEX: 6547)

Market Cap	16.34B
Revenue (ttm)	648.17M
Net Income (ttm)	-640.49M
Shares Out	328.73M
EPS (ttm)	-1.95
PE Ratio	n/a
Forward PE	54.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,856,157
Average Volume	4,843,525
Open	48.85
Previous Close	47.95
Day's Range	48.80 - 50.30
52-Week Range	33.70 - 66.00
Beta	0.79
RSI	72.61
Earnings Date	Mar 18, 2025

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan. It is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; FLU Quadrivalent, which is in Phase III clinical trial for the treatment of influenza viruses; dengue vaccine, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 103
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6547

Financial Performance

In 2023, Medigen Vaccine Biologics's revenue was 389.62 million, an increase of 6.73% compared to the previous year's 365.04 million. Losses were -1.16 billion, -21.34% less than in 2022.